Jim Slattery
4PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Nov 16, 2020
Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data.Andrej Segec, Jim Slattery, Daniel R Morales
|Oct 25, 2020
What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?Justina Januskiene, Andrej Segec, Jim Slattery
|Apr 18, 2020
Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?Jim Slattery, Xavier Kurz
|Mar 28, 2017
Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.Jacoline C Bouvy, Kevin Blake, Jim Slattery
Pageof 1
